I. MODIFIED AGREEMENTS

Company*
(Country;
Symbol)

Company
(Country;
Symbol)

Type/Product Area

Terms/Details (Date)


Alteon Inc.
(AMEX:ALT)

BioRap Technologies Ltd.*

Expanded licensing agreement for all diagnostic devices or products for predictive purposes in vascular or cardiac diseases

Alteon agreed to make research and milestone payments, as well as royalty payments, upon commercialization of any diagnostic or therapeutic products related to the licensed technology (4/6)

Argenta
Discovery
Ltd.*
(UK)

Genentech Inc. (NYSE:DNA)

Expanded drug discovery agreement to add a second two-year discovery project

The companies are using Argenta's computer aided drug design, medicinal chemistry and biology technologies to discover new chemical entities acting against a second, undisclosed drug target (3/2)

Cannasat
Therapeutics
Inc.
(Canada;
CDNX:CTH)

IntelGenx Corp. (Canada; OTC BB: IGXT)

Expanded collaboration to include a second compound in a November 2006 deal to develop a cannabis-derived drug candidate

IntelGenx will develop and apply drug delivery technologies to two preclinical cannabinoid-based products; it also will manufacture the products (3/20)

Immunicon
Corp.
(IMMC)

Kreatech Biotechnology BV* (the Netherlands)

Expanded research collaboration from January 2006 related to centromere probes

Under the new exclusive, cross-license agreement, Immunicon provided rights to Kreatech to use certain technologies to improve existing Kreatech products and to manufacture and supply those products for sale by Immunicon in North America; Immunicon agreed to make a $1.5M equity investment in Kreatech based on the achievement of certain development milestones (4/5)

Seattle
Genetics
Inc.
(SGEN)

Genentech Inc. (NYSE:DNA)

Genentech exercised exclusive licenses to specific targets and extended the research term under the 2002 antibody-drug conjugate collaboration

Genentech paid $4.5M for the exercise and has rights to use Seattle Genetics' ADC technology with antibodies against selected targets; Seattle Genetics is entitled to receive fees, progress-dependent milestones and royalties (3/27)

TorreyPines
Therapeutics
Inc.
(TPTX)

Eisai Co. Ltd. (PK:ESALF)

Extended collaboration focusing on the discovery of novel, small molecules to treat Alzheimer's disease

The original agreement gave Eisai exclusive rights of first negotiation and refusal for validated compounds discovered through the research (2/22)

Vivalis*
(France)

GeoVax Inc. (OTC BB:GOVX)

Extended collaboration from April 2005 to evaluate the use of Vivalis' avian embryonic stem cell-derived EBx cell lines as a production platform for GeoVax's MVA-based AIDS vaccine

The collaboration already has proven that the EBx technology can replicate GeoVax's specific recombinant AIDS vaccine viruses, and it will now focus on scale-up and regulatory requirements (4/17)


Notes:
* Private companies are indicated with an asterisk.
Unless otherwise noted, stock symbols listed are on the Nasdaq market.
AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; NYSE = New York Stock Exchange;
OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets.

No Comments